Validation of a treatment-selection rule for patients with advanced stage ovarian cancer

Purpose of investigation: To externally validate the rule of Van Meurs et al. for selecting patients with advanced epithelial ovarian cancer for treatment with primary surgery or neoadjuvant chemotherapy (NACT). Materials and Methods: We analysed a historical cohort of 900 consecutive patients with FIGO stage IIIC/IV ovarian cancer treated for advanced stage epithelial ovarian cancer at the Centre of Gynaecologic Oncology Amsterdam between 1998 and 2012. To externally validate the treatment-selection rule of Van Meurs et al. four groups were defined based on metastatic tumour size (smaller or larger than 45 mm) and FIGO stage (IIIC vs. IV). Within these groups, we compared survival outcomes of primary surgery and NACT. Results: Differential treatment benefit in model-defined subgroups based on metastatic tumour size and FIGO stage was confirmed (interaction p = 0.008). Survival after primary surgery was significantly better compared to NACT plus interval debulking surgery for patients in FIGO stage IIIC (p = 0.001) or IV (p = 0.028) with metastases ≤ 45 mm, and those in FIGO stage IIIC with metastases > 45 mm (p = 0.011). Survival was not significantly worse for FIGO stage IV patients with metastases > 45 mm (p = 0.094). In patients with such large metastases, the location (omentum versus elsewhere in the body) was not prognostic (p = 0.44). Conclusion: Our study has externally validated the treatment-selection rule first described by van Meurs et al. Primary surgery was shown to be superior for all patients except for the FIGO stage IV patients with a large metastatic tumour size (> 45 mm), irrespective of localisation of the metastasis.

Ovarian cancer; Treatment strategy; Overall survival; FIGO stage; Metastasis.

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2012”. Ca. Cancer J. Clin., 2012, 62, 10-29.

[2] Rutten M.J., Leeflang M.M.G., Kenter G.G., Mol B.W.J., Buist M.: “Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer”. Cochrane Database Syst. Rev., 2014, 21, CD009786.

[3] van Meurs H.S., Tajik P., Hof M.H.P., Vergote I., Kenter G.G., Mol B.W.J., et al.: “Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European organisation for research and treatment of cancer 55971 randomised trial”. Eur. J. Cancer, 2013, 49, 3191-3201.

[4] Makar A.P., Tropé C.G., Tummers P., Denys H., Vandecasteele K.: “Advanced ovarian cancer: primary or interval debulking? five categories of patients in view of the results of randomized trials and tumor biology: Primary debulking surgery and interval debulking surgery for advanced ovarian cancer”. Oncologist, 2016, 21, 745-754.

[5] Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., John-son N., et al.: “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer”. N. Engl. J. Med., 2010, 363, 943-953.

[6] Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T., et al.: “Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial”. Lancet, 2015, 386, 249-257.

[7] Morrison J., Swanton A., Collins S., Kehoe S.: “Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer”. Cochrane Database Syst. Rev., 2007, 117, CD005343.

[8] Vergote I., Tropé C.G., Amant F., Ehlen T., Reed N.S., Casado A.: “Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIC to IV ovarian cancer”. J. Clin. Oncol., 2011, 29, 4076-4078.

[9] Chi D.S., Bristow R.E., Armstrong D.K., Karlan B.Y.: “Is the easier way ever the better way?”. J. Clin. Oncol., 2011, 29, 4073-4075.

[10] Bristow R.E., Eisenhauer E.L., Santillan A., Chi D.S.: “Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduc-tion”. Gynecol. Oncol., 2007, 104, 480-490.

[11] Vergote I.B., Van Nieuwenhuysen E., Vanderstichele A.: “How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma”. J. Clin. Oncol., 2016, 34, 3827-3828.

[12] Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P.: “Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients”. Gynecol. Oncol., 1998, 71, 431-436.

[13] Wright A.A., Bohlke K., Armstrong D.K., Bookman M.A., Cliby W. A., Coleman R.L., et al.: “Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of gynecologic oncology and american society of clinical oncology clinical practice guideline”. Gynecol. Oncol., 2016, 143, 3-15.

[14] Rutten M.J., van de Vrie R., Bruining A., Spijkerboer A.M., Mol B. W., Kenter G.G., et al.: “Predicting surgical outcome in patients with international federation of gynecology and obstetrics stage III or IV ovarian cancer using computed tomography”. Int. J. Gynecol. Cancer, 2015, 25, 407-415.

[15] Rutten M.J., van Meurs H.S., van de Vrie R., Gaarenstroom K.N., Naaktgeboren C.A., van Gorp T., et al.: “Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: A randomized controlled trial”. J. Clin. Oncol., 2017, 35, 613-621.

[16] van Driel W.J., Koole S.N., Sikorska K., Schagen van Leeuwen J. H., Schreuder H.W.R., Hermans R.H.M., et al.: “Hyperthermic intraperitoneal chemotherapy in ovarian cancer”. N. Engl. J. Med., 2018, 378, 230-240.

[17] Meyer L.A., Cronin A.M., Sun C.C., Bixel K., Bookman M.A., Cristea M.C., et al.: “Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer”. J. Clin. Oncol., 2016, 34, 3854-3863.

[18] Fagotti A., Ferrandina G., Fanfani F., Garganese G., Vizzielli G., Carone V., et al.: “Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma”. Am. J. Obstet. Gynecol., 2008, 199, 642.e1-642.e6.

[19] Collins G.S., de Groot J.A., Dutton S., Omar O., Shanyinde M., Tajar A., et al.: “External validation of multivariable prediction models: a systematic review of methodological conduct and reporting”. BMC Med. Res. Methodol., 2014, 14, 40.